<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05402566</url>
  </required_header>
  <id_info>
    <org_study_id>DMI-AD</org_study_id>
    <nct_id>NCT05402566</nct_id>
  </id_info>
  <brief_title>MRI Assessment of Impaired Glucose Metabolism in Alzheimer's Disease</brief_title>
  <official_title>MRI Assessment of Impaired Glucose Metabolism in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diseases of dementia are chronic, untreatable, and cause a massive burden of morbidity. In&#xD;
      this proposal, we seek to tackle the problem of better, earlier, and more efficient diagnosis&#xD;
      using deuterium metabolic imaging (DMI). The study is divided in two sub-studies: 1)&#xD;
      optimization and simplification of DMI protocols, and 2) a cross-sectional study of DMI in&#xD;
      Alzheimer's patients and healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 13, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Deuterium Metabolic Imaging</measure>
    <time_frame>Up to 150 mins after 2H-glucose ingestion</time_frame>
    <description>Glucose concentration in whole-brain referenced to baseline scan (sub-study 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deuterium Metabolic Imaging</measure>
    <time_frame>Up to 150 mins after 2H-glucose ingestion</time_frame>
    <description>Lactate concentrations in whole-brain referenced to baseline scan (sub-study 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deuterium Metabolic Imaging</measure>
    <time_frame>Up to 150 mins after 2H-glucose ingestion</time_frame>
    <description>Glx concentrations in whole-brain referenced to baseline scan (sub-study 1).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deuterium Metabolic Imaging</measure>
    <time_frame>Up to 150 mins after 2H-glucose ingestion</time_frame>
    <description>Lactate/glx ratio in the tempo-parietal cortex (sub-study 2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deuterium Metabolic Imaging</measure>
    <time_frame>Up to 150 mins after 2H-glucose ingestion</time_frame>
    <description>Lactate/glx ratio in the hippocampus (sub-study 2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Deuterium Metabolic Imaging</measure>
    <time_frame>Up to 150 mins after 2H-glucose ingestion</time_frame>
    <description>Lactate/glx ratio in the posterior cingulum (sub-study 2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deuterium Metabolic Imaging</measure>
    <time_frame>Up to 150 mins after 2H-glucose ingestion</time_frame>
    <description>Simpler DMI quantifications, including reference to external phantoms and internal reference, in the same regions defined in primary outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples</measure>
    <time_frame>Up to 150 mins after 2H-glucose ingestion</time_frame>
    <description>Glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples</measure>
    <time_frame>Up to 150 mins after 2H-glucose ingestion</time_frame>
    <description>2H-enrichment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FDG-PET from the records (sub study 2)</measure>
    <time_frame>At time of Deuterium Metabolic Imaging</time_frame>
    <description>Brain glucose uptake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive tests from the records (sub study 2)</measure>
    <time_frame>At time of Deuterium Metabolic Imaging</time_frame>
    <description>The Mini-Mental State Exam (0-30, 30 is best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive tests from the records (sub study 2)</measure>
    <time_frame>At time of Deuterium Metabolic Imaging</time_frame>
    <description>Addenbrooke's Cognitive Examination (0-100, 100 is best)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid biochemistry from the records (sub study 2)</measure>
    <time_frame>At time of Deuterium Metabolic Imaging</time_frame>
    <description>Total tau protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid biochemistry from the records (sub study 2)</measure>
    <time_frame>At time of Deuterium Metabolic Imaging</time_frame>
    <description>Phosphorylated tau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid biochemistry from the records (sub study 2)</measure>
    <time_frame>At time of Deuterium Metabolic Imaging</time_frame>
    <description>Amyloid</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Healhy volunteers</arm_group_label>
    <description>Repeated MRI and DMI for simplification of protocols. Repeated within 6 +/- 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer's disease patients</arm_group_label>
    <description>MRI and DMI to assess cerebral glucose metabolism. Single examination. Compared with PET.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>MRI and DMI for comparison with AD patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Deuterium metabolic imaging</intervention_name>
    <description>MRI after oral administration of 75g of [6,6'-2H2]glucose.</description>
    <arm_group_label>Alzheimer's disease patients</arm_group_label>
    <arm_group_label>Healhy volunteers</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In sub-study 1, the population is composed of healthy volunteers. In sub-study 2, patients&#xD;
        with Alzheimer's disease and healthy age-matched controls are recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        AD-patients:&#xD;
&#xD;
          -  Aged 55-85 years.&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
          -  AD diagnosis by the NIA-AA 2011 research criteria.8&#xD;
&#xD;
          -  Able to give written informed consent.&#xD;
&#xD;
          -  Mini-mental state examination (MMSE) equal to or above 18.9&#xD;
&#xD;
          -  Brain FDG-PET performed at Aarhus University Hospital consistent with AD.&#xD;
&#xD;
        Healthy participants:&#xD;
&#xD;
          -  Aged 18-85 years.&#xD;
&#xD;
          -  Male or female.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        All participants:&#xD;
&#xD;
          -  Diabetes or any other metabolic disease.&#xD;
&#xD;
          -  Other significant brain disease:&#xD;
&#xD;
               -  Strokes.&#xD;
&#xD;
               -  Tumors.&#xD;
&#xD;
               -  Chronic small vessel disease (clinically suspected, or Fazekas ≥ 2 if clinical&#xD;
                  MRI is available).&#xD;
&#xD;
               -  Epilepsy.&#xD;
&#xD;
               -  Other neurodegenerative or -inflammatory disease.&#xD;
&#xD;
          -  Contraindications for MRI:&#xD;
&#xD;
               -  Pacemaker, neurostimulator or cochlear implant.&#xD;
&#xD;
               -  Metal foreign bodies such as fragments and irremovable piercings.&#xD;
&#xD;
               -  Unsafe medical implants (safety of heart valves, hips and the like must be&#xD;
                  confirmed).&#xD;
&#xD;
               -  Claustrophobia.&#xD;
&#xD;
               -  Largest circumference including arms &gt; 160 cm.&#xD;
&#xD;
          -  Pregnant - women must be post-menopausal or confirmed non-pregnant by an onsite test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Nikolaj Bøgh, MD</last_name>
    <phone>+45 78 45 61 39</phone>
    <email>nikolaj.boegh@clin.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus University</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaj Bøgh, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>May 25, 2022</study_first_submitted>
  <study_first_submitted_qc>May 30, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2022</study_first_posted>
  <last_update_submitted>May 30, 2022</last_update_submitted>
  <last_update_submitted_qc>May 30, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared after study completion and full anonymization.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>After study is completed.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

